

Author's Accepted Manuscript

Estimate of opportunistic prostate-specific antigen testing in the Finnish
Randomized Study of Screening for Prostate Cancer

Tuomas P. Kilpeläinen , Dimitri Pogodin-Hannolainen , Kimmo Kempainen , Kirsi
Talala , Jani Raitanen , Kimmo Taari , Paula Kujala , Teuvo L.J. Tammela , Anssi
Auvinen



PII: S0022-5347(17)30074-5
DOI: [10.1016/j.juro.2017.01.048](https://doi.org/10.1016/j.juro.2017.01.048)
Reference: JURO 14322

To appear in: *The Journal of Urology*

Please cite this article as: Kilpeläinen TP, Pogodin-Hannolainen D, Kempainen K, Talala K, Raitanen J, Taari K, Kujala P, Tammela TLJ, Auvinen A, Estimate of opportunistic prostate-specific antigen testing in the Finnish Randomized Study of Screening for Prostate Cancer, *The Journal of Urology*® (2017), doi: 10.1016/j.juro.2017.01.048.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Embargo Policy

All article content is under embargo until uncorrected proof of the article becomes available online.

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.

Estimate of opportunistic prostate-specific antigen testing in the Finnish Randomized Study of Screening for Prostate Cancer

Running head: Contamination in the Finnish section of ERSPC

Tuomas P. Kilpeläinen * (a) tuomas.kilpelainen@hus.fi

Dimitri Pogodin-Hannolainen*(b) poghan@gmail.com

Kimmo Kempainen (c) kimmo.kempahainen@gmail.com

Kirsi Talala (d) kirsi.talala@cancer.fi

Jani Raitanen (c, e) jani.raitanen@staff.uta.fi

Kimmo Taari (a) kimmo.taari@hus.fi

Paula Kujala (f) paula.kujala@pshp.fi

Teuvo L.J. Tammela (g) teuvo.tammela@uta.fi

Anssi Auvinen (c) anssi.auvinen@staff.uta.fi

*equal contribution

a Dept. of Urology, University of Helsinki and Helsinki University Hospital, FI-00029 Helsinki, Finland

b Dept. of Urology, Kanta-Häme Central Hospital, FI-13530 Hämeenlinna, Finland

c School of Health Sciences, University of Tampere, FI-33014 Tampere, Finland

d Finnish Cancer Registry, FI-00130 Helsinki, Finland

e UKK Institute for Health Promotion Research, FI-33501 Tampere, Finland

f Fimlab Laboratories, Department of Pathology, Tampere University Hospital, FI-33521 Tampere, Finland

g Dept. of Urology, University of Tampere and Tampere University Hospital, FI-33521 Tampere, Finland

Corresponding author:

Tuomas P. Kilpeläinen, M.D., Ph.D., FEBU. Dept. of Urology, University of Helsinki and Helsinki University Hospital, FI-00029 Helsinki, Finland. E-mail: tuomas.kilpelainen@hus.fi. Phone: +358504271014. Fax: +358947166684

Word count 2,499 (limit 2500)

Word count of the abstract 240 (limit 250)

Figures 4

Tables 2

Keywords *Mortality; Prostate cancer; Prostate-specific antigen; Randomized controlled trials; Screening*

Download English Version:

<https://daneshyari.com/en/article/5687135>

Download Persian Version:

<https://daneshyari.com/article/5687135>

[Daneshyari.com](https://daneshyari.com)